LifeStance  Health Q2 revenue beats estimates

LifeStance Health

07/08/2025 11:10

Overview

LifeStance  Health Group Q2 revenue rises 11% to $345.3 mln, beating analyst expectations

Net loss of $3.8 mln beats analyst estimates

Adjusted EBITDA increases 19% to $34 mln, exceeding analyst estimates

Outlook

Company reiterates full-year revenue of $1.40 bln to $1.44 bln

Lifestance raises full-year Adjusted EBITDA to $140 mln to $150 mln

Company expects Q3 revenue of $345 mln to $365 mln

Lifestance sees Q3 Adjusted EBITDA of $33 mln to $39 mln

Result Drivers

CLINICIAN GROWTH - Revenue growth driven by 11% increase in clinician base, resulting in higher visit volumes

OPERATING LEVERAGE - Adjusted EBITDA rose due to revenue growing faster than general and administrative expenses

FREE CASH FLOW - Strong free cash flow of $57 mln attributed to improved operational performance

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$345.30 mln
$345.20 mln (8 Analysts)
Q2 Net Income
Beat
-$3.80 mln
-$9.87 mln (6 Analysts)
Q2 Adjusted EBITDA
Beat
$34 mln
$31.10 mln (7 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for LifeStance Health Group Inc is $8.25, about 52.7% above its August 6 closing price of $3.90

Press Release: ID:nGNX6l7jZx

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)